Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain Research Institute I+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
Nephrol Dial Transplant. 2016 Jan;31(1):150-60. doi: 10.1093/ndt/gfv308. Epub 2015 Aug 30.
We previously reported that preformed anti-MHC class I-related chain A (MICA) antibodies increase the risk for renal graft rejection and enhance the deleterious effect of PRA(+) status early after transplantation.
We studied 727 kidney recipients. Days to reach optimal serum creatinine level, estimated glomerular filtration rate (eGFR) at Month 3 and chronic kidney disease (CKD) stages were recorded. Anti-MICA specificities and C1q binding were tested by solid-phase assay. Complement-dependent cytotoxicity (CDC) and flow cytometry (FC) cross-matches with HeLa and PMA/CD28-T-blasts were performed.
PRA(+)MICA(+) recipients exhibited longer time to reach optimal serum creatinine level after transplantation (P = 0.005) and had the lowest eGFR at Month 3 (P = 0.006). PRA(+)MICA(+) status independently increased the risk for CKDT stage 5 at Month 3 [hazard ratio (HR) 4.92, P = 0.030]. Pre-transplant anti-MICA antibodies were polyspecific and showed stronger reactions when coexisting with anti-HLA antibodies (mean standard fluorescent intensity 112 157 ± 44 426 in HLA(+)MICA(+) sera versus 49 680 ± 33 116 in HLA(-)MICA(+) sera, P = 0.0006). Anti-AYVE supereplet reactivity was significantly higher in HLA(+)MICA(+) versus HLA(-)MICA(+) patients (P < 0.001) and significantly superior than anti-CMGWS supereplet within HLA(+)MICA(+) patients (P = 0.001). Three of 13 anti-MICA(+) pre-transplant sera were positive for the C1q binding assay; one of them (serum 3) exclusively recognized AYVE supereplet with a strong reactivity against MICA027 antigen (same as MICA008). Anti-MICA antibodies in anti-HLA-absorbed serum 3 bound native MICA molecules in MICA*008(+) HeLa and PMA/CD28-T-blasts and mediated cell death by activating complement.
Preformed anti-MICA antibodies may occasionally be cytotoxic by fixing and activating complement. This way they might contribute to worse early kidney graft function.
我们之前报道过,预先形成的抗主要组织相容性复合体Ⅰ类相关链 A(MICA)抗体增加了肾移植排斥的风险,并在移植后早期增强了 PRA(+)状态的有害影响。
我们研究了 727 名肾移植受者。记录达到最佳血清肌酐水平的天数、移植后第 3 个月的估算肾小球滤过率(eGFR)和慢性肾脏病(CKD)分期。通过固相法检测抗 MICA 特异性和 C1q 结合。进行补体依赖性细胞毒性(CDC)和流式细胞术(FC)与 HeLa 和 PMA/CD28-T blasts 的交叉匹配。
PRA(+)MICA(+)受者在移植后达到最佳血清肌酐水平的时间更长(P=0.005),并且在第 3 个月时 eGFR 最低(P=0.006)。PRA(+)MICA(+)状态独立增加了第 3 个月时 CKD T 分期 5 的风险[危险比(HR)4.92,P=0.030]。移植前抗 MICA 抗体是多特异性的,并且当与抗 HLA 抗体共存时反应更强(HLA(+)MICA(+)血清中的平均标准荧光强度为 112157±44426,而 HLA(-)MICA(+)血清中的平均标准荧光强度为 49680±33116,P=0.0006)。与 HLA(-)MICA(+)患者相比,HLA(+)MICA(+)患者的抗-AYVE 超集反应性明显更高(P<0.001),并且在 HLA(+)MICA(+)患者中明显优于抗-CMGWS 超集反应性(P=0.001)。在 13 份移植前抗-MICA(+)血清中有 3 份对 C1q 结合试验呈阳性;其中一份(血清 3)仅识别 AYVE 超集,对 MICA027 抗原有强烈反应(与 MICA008 相同)。抗 HLA 吸收的血清 3 中的抗-MICA 抗体结合了 MICA*008(+)HeLa 和 PMA/CD28-T-blasts 中的天然 MICA 分子,并通过激活补体介导细胞死亡。
预先形成的抗-MICA 抗体偶尔可能通过固定和激活补体而具有细胞毒性。这样,它们可能会导致早期肾脏移植物功能更差。